Core Viewpoint - Rosen Law Firm is reminding purchasers of Outset Medical, Inc. securities of the upcoming lead plaintiff deadline for a class action lawsuit related to misleading statements made by the company during the class period from August 1, 2022, to August 7, 2024 [1]. Group 1: Class Action Details - Investors who purchased Outset Medical securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by October 28, 2024 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Case Background - The lawsuit alleges that during the class period, Outset Medical made false and misleading statements regarding its Tablo products, including marketing for unapproved uses and lacking the necessary sales infrastructure [5]. - Specific claims include that Outset Medical was likely to submit an additional 510(k) application for the Tablo products and that there was a substantial risk of ceasing sales pending FDA approval [5]. - The lawsuit asserts that these misleading statements adversely impacted the company's revenue growth and caused investor damages when the truth was revealed [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been recognized as a leader in the field of securities class action litigation [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Outset Medical, Inc. regarding a class action lawsuit due to alleged misleading statements and omissions related to the company's Tablo products used in dialysis care [1][2]. Summary by Sections Class Period and Allegations - The class period for the lawsuit is from August 1, 2022, to August 7, 2024 [2]. - Allegations include that Outset Medical marketed its Tablo products for uses not approved by the FDA, which could lead to a need for additional regulatory applications [2]. - There is a substantial risk that the company may have to cease sales of Tablo products pending FDA approval for additional indications [2]. - The company reportedly lacked the necessary sales team and processes to effectively ramp up Tablo sales, which would adversely impact revenue growth [2]. - Positive statements made by the defendants regarding the company's business and prospects were claimed to be materially misleading [2]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by the deadline of October 28, 2024, to potentially become lead plaintiffs [3]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle [3]. About the Gross Law Firm - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4].

SAN DIEGO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Outset Medical, Inc. (NASDAQ: OM) securities between August 1, 2022 and August 7, 2024. Outset Medical is a medical technology company. Its primary products are the Tablo series devices used in dialysis care, including the Tablo Hemodialysis System and the TabloCart. For more information, submit a form, email attorney A ...

Core Viewpoint - A class action securities lawsuit has been filed against Outset Medical, alleging securities fraud that affected investors between August 1, 2022, and August 7, 2024 [1]. Group 1: Lawsuit Details - The complaint claims that Outset Medical made false statements regarding its Tablo products, which were marketed for uses not approved by the FDA [2]. - It is alleged that Outset Medical was likely to submit an additional 510(k) application for the Tablo products due to these misrepresentations [2]. - The lawsuit indicates a substantial risk that Outset Medical would have to cease sales of the Tablo products pending FDA approval of additional indications [2]. - The company reportedly lacked the necessary sales team and processes to effectively ramp up Tablo sales, which would adversely impact revenue growth [2]. - Defendants' positive statements about the company's business and prospects were claimed to be materially misleading and lacked a reasonable basis [2]. Group 2: Next Steps for Investors - Investors who suffered losses in Outset Medical during the specified timeframe have until October 28, 2024, to request appointment as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4].

NEW YORK, Sept. 16, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Outset Medical, Inc. (NASDAQ: OM). Shareholders who purchased shares of OM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/outset-medical-loss-submission-form/?id=102423&from=4 CLASS PERIOD: August 1, 2022 t ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Outset Medical, Inc. securities during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [2]. Group 1: Class Action Details - The class period for the lawsuit is from August 1, 2022, to August 7, 2024, and investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2][3]. - A class action lawsuit has already been filed, and interested parties must move the court to serve as lead plaintiff by October 28, 2024 [3]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience or resources [4]. - The Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions of dollars for investors [4]. Group 3: Case Allegations - The lawsuit alleges that during the class period, Outset Medical made false or misleading statements regarding its Tablo products, including marketing for unapproved uses and lacking the necessary sales infrastructure [5]. - The claims suggest that these misrepresentations led to adverse impacts on Outset Medical's revenue growth and misled investors about the company's business prospects [5].

SAN FRANCISCO, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Hagens Berman Outset Medical (NASDAQ: OM) investors who suffered substantial losses to submit your losses now. The firm also encourages persons with knowledge who may assist the investigation to contact its attorneys. The litigation focuses on the propriety of Outset Medical's disclosures about its business prospects and operations, specifically those concerning its Tablo Hemodialysis System ("Tablo products"). The company received Section 510(k) clearance f ...

NEW YORK, Sept. 12, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Outset Medical, Inc. (NASDAQ: OM). Shareholders who purchased shares of OM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/outset-medical-loss-submission-form/?id=101889&from=4 CLASS PERIOD: August 1, 2022 t ...

NEW YORK, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Outset Medical, Inc. ("Outset Medical" or the "Company") (NASDAQ: OM) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Outset Medical investors who were adversely affected by alleged securities fraud between August 1, 2022 and August 7, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/outset-medic ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Outset Medical, Inc. regarding a class action lawsuit due to alleged misleading statements and omissions related to the company's Tablo products used in dialysis care [1][2]. Summary by Sections Class Period and Allegations - The class period for the lawsuit is from August 1, 2022, to August 7, 2024 [2]. - Allegations include that Outset Medical marketed Tablo products for uses not approved by the FDA, which may lead to a need for additional regulatory applications [2]. - There is a substantial risk that the company could cease sales of Tablo products pending FDA approval, and the company lacks the necessary sales team and processes to effectively ramp up sales [2]. - These factors are expected to adversely impact the company's revenue growth and render previous positive statements about the business misleading [2]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by the deadline of October 28, 2024, to potentially be appointed as lead plaintiffs [3]. - Registration will provide shareholders with updates throughout the lifecycle of the case, and participation incurs no cost or obligation [3]. About the Gross Law Firm - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4].